Upstream Bio (UPB) Competitors $10.81 -0.19 (-1.73%) As of 01/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends UPB vs. EWTX, AMRX, JANX, ARWR, NAMS, PTGX, VERA, MIRM, SUPN, and CNTAShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Edgewise Therapeutics (EWTX), Amneal Pharmaceuticals (AMRX), Janux Therapeutics (JANX), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), Mirum Pharmaceuticals (MIRM), Supernus Pharmaceuticals (SUPN), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry. Upstream Bio vs. Edgewise Therapeutics Amneal Pharmaceuticals Janux Therapeutics Arrowhead Pharmaceuticals NewAmsterdam Pharma Protagonist Therapeutics Vera Therapeutics Mirum Pharmaceuticals Supernus Pharmaceuticals Centessa Pharmaceuticals Upstream Bio (NASDAQ:UPB) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, community ranking, analyst recommendations, valuation, media sentiment and institutional ownership. Which has stronger valuation and earnings, UPB or EWTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream BioN/AN/AN/AN/AN/AEdgewise TherapeuticsN/AN/A-$100.16M-$1.50-18.26 Does the media refer more to UPB or EWTX? In the previous week, Edgewise Therapeutics had 5 more articles in the media than Upstream Bio. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 0 mentions for Upstream Bio. Edgewise Therapeutics' average media sentiment score of 0.59 beat Upstream Bio's score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Upstream Bio Neutral Edgewise Therapeutics Positive Do analysts prefer UPB or EWTX? Upstream Bio currently has a consensus price target of $56.50, indicating a potential upside of 422.66%. Edgewise Therapeutics has a consensus price target of $43.17, indicating a potential upside of 57.60%. Given Upstream Bio's higher possible upside, equities research analysts plainly believe Upstream Bio is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Edgewise Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer UPB or EWTX? Edgewise Therapeutics received 30 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 73.91% of users gave Edgewise Therapeutics an outperform vote. CompanyUnderperformOutperformUpstream BioOutperform Votes4100.00% Underperform VotesNo VotesEdgewise TherapeuticsOutperform Votes3473.91% Underperform Votes1226.09% Is UPB or EWTX more profitable? Upstream Bio's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Upstream BioN/A N/A N/A Edgewise Therapeutics N/A -26.83%-25.67% SummaryUpstream Bio and Edgewise Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$589.56M$6.56B$5.38B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.3686.9417.29Price / SalesN/A329.751,267.38137.12Price / CashN/A22.6336.6032.88Price / BookN/A5.084.974.69Net IncomeN/A$154.90M$117.89M$224.57M7 Day Performance-9.92%1.33%1.72%1.69%1 Month Performance-33.31%1.51%3.67%5.34%1 Year PerformanceN/A4.60%26.11%21.47% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream BioN/A$10.81-1.7%$56.50+422.7%N/A$589.56MN/A0.0038EWTXEdgewise Therapeutics2.1524 of 5 stars$25.33+4.9%$43.17+70.4%+110.0%$2.40BN/A-16.8960Short Interest ↑AMRXAmneal Pharmaceuticals3.3782 of 5 stars$7.72-3.1%$10.00+29.5%+58.5%$2.39B$2.68B-11.357,700JANXJanux Therapeutics3.5227 of 5 stars$45.06-3.6%$89.90+99.5%+342.3%$2.36B$13.05M-38.5130ARWRArrowhead Pharmaceuticals4.1987 of 5 stars$18.91+2.3%$43.33+129.2%-41.5%$2.35B$3.55M-3.77400NAMSNewAmsterdam Pharma2.7382 of 5 stars$24.58-1.5%$38.17+55.3%+21.5%$2.27B$33.59M0.004PTGXProtagonist Therapeutics2.8849 of 5 stars$37.14+1.4%$53.78+44.8%+53.8%$2.21B$323.80M13.96120VERAVera Therapeutics2.2468 of 5 stars$34.77-6.1%$63.50+82.6%+125.7%$2.20BN/A-13.3240High Trading VolumeMIRMMirum Pharmaceuticals4.0223 of 5 stars$44.00+6.5%$57.10+29.8%+82.2%$2.11B$307.03M-21.78140Insider TradeSUPNSupernus Pharmaceuticals3.7402 of 5 stars$37.57+0.2%$46.50+23.8%+39.4%$2.07B$651.97M35.11580Positive NewsCNTACentessa Pharmaceuticals2.8865 of 5 stars$15.26-2.4%$25.83+69.3%+103.2%$2.01B$6.85M-9.97200 Related Companies and Tools Related Companies EWTX Alternatives AMRX Alternatives JANX Alternatives ARWR Alternatives NAMS Alternatives PTGX Alternatives VERA Alternatives MIRM Alternatives SUPN Alternatives CNTA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UPB) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
